RxDoctor Payments Data

Carlos D'assumpcao, MD

Infectious Disease · Bakersfield, CANPI 1053806067

Payments from drug & device makers

$2,166in general payments, 2019–2025

Across 73 payments — averaging $29.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$767
  • Shionogi Inc$518
  • AbbVie$344
  • La Jolla Pharmaceutical Company$142
  • Biomerieux Inc$121
  • Melinta Therapeutics, LLC$75
  • plus $198 from 6 others

What the payments were for

  • Food & beverage$1,80783%
  • Education$35817%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,166 in reported general payments places this provider in the 65th percentile of 856 infectious disease providers in California.

See all infectious disease providers in California

Medicare billing

Part B allowed, 2024
$36,821
Medicare patients
129
Services billed
402

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CresembaIsavuconazonium Sulfate55$351,008
BiktarvyBictegrav/Emtricit/Tenofov Ala31$131,307
TriumeqAbacavir/Dolutegravir/Lamivudi22$86,975
Posaconazole43$80,262
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$54,467
DovatoDolutegravir Sodium/Lamivudine12$34,211
Etravirine11$12,138
Fluconazole24$2,362
Entecavir16$1,136
Itraconazole12$1,127
Doxycycline Hyclate18$525
Rifampin13$489
Ethambutol Hcl12$402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncCresemba$767$351,00855 claims
GileadBiktarvy, Genvoya$70$185,77443 claims
Viiv Healthcare CompanyTriumeq, Dovato$40$121,18634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 856 infectious disease providers in California.

Other infectious disease in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →